2019 March 19 Nature.com Scientific Reports, volume 9, Article number: 4847

Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics.

Advances in biotechnology have led to the development of a number of biological therapies for the treatment of diverse human diseases. Since these products may contain or are made using human or animal (e.g. cattle) derived materials, it is crucial to test their safety by ensuring the absence of infectious agents; specifically prions, which are highly resilient to elimination and produce fatal diseases in humans.

Authors: Adam Lyon, Charles E. Mays, Frank Borriello, Glenn C. Telling, Claudio Soto, Sandra Pritzkow

Link to Article